2020 oil, gas, and chemical industry outlook

February 26, 2020

As we, once again, move from one year to the next, how do we assess the oil and gas and chemical sectors’ performance in 2019 and its prospects for 2020? As always, there are headwinds and tailwinds, risks and opportunities, uncertainties and foreseeable trends, but in this report we aim to take stock of the main factors to watch for in 2020 across the diverse oil, gas, and chemical industry.

Spotlight

AcelRx Pharmaceuticals, Inc

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company’s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A

OTHER WHITEPAPERS
news image

Chemical Engineering Essentials for the CPL Professional

whitePaper | January 9, 2023

For more than 120 years, Chemical Engineering has been the leading source for news, technology and analysis used by engineers, operators, plant managers, senior managers and consultants worldwide.

Read More
news image

Flow Measurement for Emissions Monitoring

whitePaper | February 25, 2023

Monitoring emissions has been a major concern at industrial sites, including those in the chemical process industries (CPI), for the past few decades, but a number of factors are currently aligned that elevate the importance of proper monitoring, and amplify the consequences of failing to do so reliably and accurately.

Read More
news image

Lithium batteries whitepaper

whitePaper | December 25, 2022

Founded in 1903, Brookes Bell is a leading multi-disciplinary technical and scientific consultancy serving the marine and energy sectors. We investigate, troubleshoot and advise on a broad range of marine and energy matters and enjoy a reputation.

Read More
news image

We create chemistry for a sustainable future

whitePaper | March 24, 2023

This presentation contains forward-looking statements. These statements are based on current estimates and projections of the Board of Executive Directors and currently available information. Forward-looking statements are not guarantees of the future developments and results outlined therein.

Read More
news image

Cyber Resilience in the Oil and Gas Industry: Playbook for Boards and Corporate Officers

whitePaper | May 17, 2021

To help the energy industry improve its resilience against cyber risk, the World Economic Forum has convened over 40 senior executives to establish a blueprint for evaluating cyber risk across the oil and gas industry. This White Paper is the result of their in-depth discussions to illuminate the industry’s best practices and create new solutions for corporate leaders to address cyber risk. It presents six principles to help boards at oil and gas companies govern this risk and strengthen their organization’s cyber resilience. Adopting them will support the industry in its efforts to continue delivering safe, affordable and low-carbon energy for decades to come.

Read More
news image

Validation of Titration Methods

whitePaper | September 8, 2022

The quality of your product depends on the analyses performed in quality control. That is why you rely on first-rate analytical instruments for the most accurate and precise results, and product quality

Read More

Spotlight

AcelRx Pharmaceuticals, Inc

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company’s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A

Events